Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

4 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
4(66.7%)
Phase 2
2(33.3%)
6Total
Phase 3(4)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials
NCT01314833Phase 3Completed

Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy

Role: collaborator

NCT01216111Phase 3Completed

Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)

Role: collaborator

NCT03351062Phase 3Unknown

Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

Role: lead

NCT03151044Phase 3Unknown

R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL

Role: collaborator

NCT02593435Unknown

The Registration Program of BRCA1/2 Gene

Role: lead

NCT02263846Completed

Investigation of Sex Hormone Levels in Chinese Women With Invasive Breast Cancer

Role: collaborator

NCT01934829Phase 2Completed

Urea Cream Treatment Sorafenib-Associated HSFR in HCC

Role: lead

NCT01779531Unknown

Compare the Outcomes of XT and XEC Adjuvant Chemotherapy in HER2-negative Luminal B Breast Cancer Patients

Role: collaborator

NCT01216124Unknown

Efficacy and Safety Study of Neoadjuvant Chemotherapy for Local Advanced Triple Negative Breast Cancer Patients

Role: collaborator

NCT00826891Phase 2Unknown

Study of Cisplatin in Cervical Cancer Stage IVB

Role: lead

All 10 trials loaded